Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
September 29 2021 - 07:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors (KORs), today announced that
results from the KARE Phase 2 clinical trial of Oral KORSUVA™
(difelikefalin tablets) for the treatment of moderate-to-severe
pruritus in mild-to-severe atopic dermatitis (AD) patients will be
presented in a late-breaking presentation at the European Academy
of Dermatology and Venereology (EADV) 30th Anniversary Congress,
held virtually from September 29-October 2, 2021.
Details for the late-breaking oral presentation
are as follows:
Title: Oral Difelikefalin
Reduces Pruritus in Atopic DermatitisAbstract
Number: D3T01.1DDate and Time: Saturday,
October 2, 2021, 10:45-11:00 CESTPresenter: Brian
S. Kim, MD, MTR, Washington University School of Medicine, St.
Louis, MO
About Cara TherapeuticsCara
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing and commercializing new chemical entities designed to
alleviate pruritus by selectively targeting peripheral kappa opioid
receptors, or KORs. Cara is developing a novel and proprietary
class of product candidates, led by KORSUVA™ (CR845/difelikefalin),
a first-in-class KOR agonist that targets the body’s peripheral
nervous system, as well as certain immune cells. KORSUVA Injection
was approved by the U.S. Food and Drug Administration (FDA) for the
treatment of moderate-to-severe pruritus associated with chronic
kidney disease (CKD-aP) in adults undergoing hemodialysis on August
23, 2021. Oral KORSUVA has completed Phase 2 trials for the
treatment of pruritus in patients with CKD and atopic dermatitis
and is currently in Phase 2 trials in primary biliary cholangitis
and notalgia paresthetica patients with moderate-to-severe
pruritus.
MEDIA CONTACT:Claire LaCagnina6
Degrees315-765-1462clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2023 to Mar 2024